TipRanks
Advertisement
Advertisement

GSK Stock Latest News

GSK enters agreement to acquire trispecific TCE from Chimagen
The FlyGSK enters agreement to acquire trispecific TCE from Chimagen
2d ago
GSK
GSK upgraded to Buy from Hold at Berenberg
PremiumThe Fly
GSK upgraded to Buy from Hold at Berenberg
2d ago
GSK
GSK presents results from phase I/II ARROS-1 trial evaluating Jideytro
PremiumThe Fly
GSK presents results from phase I/II ARROS-1 trial evaluating Jideytro
3d ago
GSK
GSK licensor Hansoh announces ARTEMIS-008 phase III trial met primary endpoint
PremiumThe Fly
GSK licensor Hansoh announces ARTEMIS-008 phase III trial met primary endpoint
3d ago
GSK
GSK announces Japan’s MHLW approved prefilled syringe presentation of Shingrix
PremiumThe Fly
GSK announces Japan’s MHLW approved prefilled syringe presentation of Shingrix
7d ago
GSK
GSK price target raised to 2,000 GBp from 1,860 GBp at HSBC
PremiumThe FlyGSK price target raised to 2,000 GBp from 1,860 GBp at HSBC
7d ago
GSK
GSK initiated with a Sector Perform at RBC Capital
Premium
The Fly
GSK initiated with a Sector Perform at RBC Capital
8d ago
GSK
GSK Boosts Q2 2026 Sales and Launches £1.9bn Accelerate Growth Programme to Fund Late-Stage R&D
Premium
Company Announcements
GSK Boosts Q2 2026 Sales and Launches £1.9bn Accelerate Growth Programme to Fund Late-Stage R&D
8d ago
6K
GSK
GSK: Pipeline Optionality Recognized but Near-Term Data Gaps Keep Rating at Hold and Price Target Unchanged at 2,350 GBp
PremiumRatings
GSK: Pipeline Optionality Recognized but Near-Term Data Gaps Keep Rating at Hold and Price Target Unchanged at 2,350 GBp
12d ago
GSK
HUTCHMED Stock (HCM) Rallies Over 15% on a Major Licensing Deal
PremiumMarket News
HUTCHMED Stock (HCM) Rallies Over 15% on a Major Licensing Deal
13d ago
GSK
HCM
Hutchmed, GSK enter HMPL-A830 commercialization agreement
PremiumThe Fly
Hutchmed, GSK enter HMPL-A830 commercialization agreement
14d ago
GSK
HCM
GSK presents phase II data from mRNA flu vaccine candidate
PremiumThe Fly
GSK presents phase II data from mRNA flu vaccine candidate
16d ago
GSK
GSK Advances Early-Stage Lung Drug With New Formulation Study
PremiumCompany AnnouncementsGSK Advances Early-Stage Lung Drug With New Formulation Study
20d ago
GSK
GSK’s Pediatric Asthma Trial Signals Long-Term Upside in Biologic Market
Premium
Company Announcements
GSK’s Pediatric Asthma Trial Signals Long-Term Upside in Biologic Market
21d ago
GSK
GSK’s ViiV Healthcare announces FDA approval of Tivicay PD
Premium
The Fly
GSK’s ViiV Healthcare announces FDA approval of Tivicay PD
21d ago
GSK
GSK price target raised to 1,900 GBp from 1,750 GBp at Morgan Stanley
PremiumThe Fly
GSK price target raised to 1,900 GBp from 1,750 GBp at Morgan Stanley
22d ago
GSK
AnaptysBio price target lowered to $70 from $75 at TD Cowen
PremiumThe Fly
AnaptysBio price target lowered to $70 from $75 at TD Cowen
23d ago
GSK
ANAB
GSK announces Japan’s MHLW approved Hibsago
PremiumThe Fly
GSK announces Japan’s MHLW approved Hibsago
24d ago
GSK
GSK announces FDA accepted for priority review a sBLA for Jemperli
PremiumThe Fly
GSK announces FDA accepted for priority review a sBLA for Jemperli
24d ago
GSK
GSK’s New COPD Bet: Felcorekibart Enters Phase 3 With Long-Term Upside Potential
PremiumCompany AnnouncementsGSK’s New COPD Bet: Felcorekibart Enters Phase 3 With Long-Term Upside Potential
26d ago
GSK
GSK’s New Phase 3 Asthma Trial Sets the Stage for the Next Wave in Respiratory Growth
Premium
Company Announcements
GSK’s New Phase 3 Asthma Trial Sets the Stage for the Next Wave in Respiratory Growth
26d ago
GSK
GSK’s New COPD Trial Puts Felcorekibart in Focus for Long-Term Respiratory Growth
Premium
Company Announcements
GSK’s New COPD Trial Puts Felcorekibart in Focus for Long-Term Respiratory Growth
26d ago
GSK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >